Pharmaceutical Investing Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin
Landmark Study Shows GeneSight Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder
Pharmaceutical Investing Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
